Sandbox carlos: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 18: Line 18:
:::* Alternative regimen (2): [[Trimethoprim-sulfamethoxazole]] 320 mg/1600 mg PO 3 times weekly
:::* Alternative regimen (2): [[Trimethoprim-sulfamethoxazole]] 320 mg/1600 mg PO 3 times weekly
:::* Alternative regimen (3): [[Pyrimethamine]] 25 mg PO qd {{and}} [[Leucovorin]] 5–10 mg PO qd
:::* Alternative regimen (3): [[Pyrimethamine]] 25 mg PO qd {{and}} [[Leucovorin]] 5–10 mg PO qd
:::* Alternative regimen (4): [[Ciprofloxacin]] 500 mg PO 3 times weekly
:::* Alternative regimen (4): [[Ciprofloxacin]] 500 mg PO 3 times weekly (second-line alternative)
:::* Note (1): Criteria for discontinuation of chronic maintenance therapy: sustained increase in CD4 count > 200 cells/mm<sup>3</sup> for > 6 months in response to ART and without evidence of active Cystoisospora belli infection
:::* Note (1): Criteria for discontinuation of chronic maintenance therapy: sustained increase in CD4 count > 200 cells/mm<sup>3</sup> for > 6 months in response to ART and without evidence of active Cystoisospora belli infection
:::* Note (2): Because of concerns about possible teratogenicity associated with first-trimester drug exposure, clinicians may withhold secondary prophylaxis during the first trimester and treat only symptomatic infection.
:::* Note (2): Because of concerns about possible teratogenicity associated with first-trimester drug exposure, clinicians may withhold secondary prophylaxis during the first trimester and treat only symptomatic infection.

Revision as of 18:01, 16 July 2015


  • 1. Cystoisospora belli treatment




  • 2. Cystoisospora belli prophylaxis[1]
  • 2.1 Primary prophylaxis
  • Insufficient evidence is available to support a general recommendation for primary prophylaxis for Cystoisosporiasis per se, especially for U.S. travelers in isoporiasis-endemic areas.
  • 2.2 Secondary prophylaxis (preventing recurrence in patients with CD4 count < 200 cells/mm3)
  • Prefered regimen: Trimethoprim-sulfamethoxazole 160 mg/800 mg PO 3 times weekly
  • Alternative regimen (1): Trimethoprim-sulfamethoxazole 160 mg/800 mg PO qd
  • Alternative regimen (2): Trimethoprim-sulfamethoxazole 320 mg/1600 mg PO 3 times weekly
  • Alternative regimen (3): Pyrimethamine 25 mg PO qd AND Leucovorin 5–10 mg PO qd
  • Alternative regimen (4): Ciprofloxacin 500 mg PO 3 times weekly (second-line alternative)
  • Note (1): Criteria for discontinuation of chronic maintenance therapy: sustained increase in CD4 count > 200 cells/mm3 for > 6 months in response to ART and without evidence of active Cystoisospora belli infection
  • Note (2): Because of concerns about possible teratogenicity associated with first-trimester drug exposure, clinicians may withhold secondary prophylaxis during the first trimester and treat only symptomatic infection.


  • Immunocompetent
  • 1. Patients with sulfa intolerance
  • Alternative regimen (1): Pyrimethamine 50-75 mg PO daily AND Leucovorin 10–25 mg PO daily
  • Alternative regimen (2): Ciprofloxacin 500 mg PO BID for 7 days


  • HIV
  • 1. Patients with CD4 Count <200/mm3 (chronic treatment)


References

  1. "Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents" (PDF).